Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 20, 2009

Primary Completion Date

November 28, 2009

Study Completion Date

November 28, 2009

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

GSK2248761

GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.

DRUG

Lopinavir/ritonavir

Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.

DRUG

HAART

Highly Active Antiretroviral therapy of the doctor's choice.

DRUG

Placebo

Placebo is a capsule with no drug in it.

DRUG

GSK2248761

GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.

Trial Locations (1)

B1602DBG

GSK Investigational Site, Buenos Aires

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY